在局部晚期基底细胞癌中，对索尼德吉产生继发性耐药的情况较为罕见。 - Suppr

Suppr

超能文献

Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma.

作者信息

Muñoz Couselo Eva, Berking Carola, Baurain Jean François, Martelli Serena, Arntz Ramon, Savoia Paola

机构信息

Vall d'Hebron Hospital Universitari, Barcelona, Spain.

Vall d'Hebron Institute of Oncology, Barcelona, Spain.

出版信息

J Eur Acad Dermatol Venereol. 2025 Sep;39(9):e788-e790. doi: 10.1111/jdv.20629. Epub 2025 Mar 8.

DOI:10.1111/jdv.20629

PMID:40055950

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12376237/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b73d/12376237/f779c7de3c3d/JDV-39-e788-g001.jpg

相似文献

Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma.在局部晚期基底细胞癌中，对索尼德吉产生继发性耐药的情况较为罕见。

J Eur Acad Dermatol Venereol. 2025 Sep;39(9):e788-e790. doi: 10.1111/jdv.20629. Epub 2025 Mar 8.

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.两种不同剂量的 sonidegib 治疗局部晚期或转移性基底细胞癌（BOLT）患者：一项多中心、随机、双盲 2 期试验。

Lancet Oncol. 2015 Jun;16(6):716-28. doi: 10.1016/S1470-2045(15)70100-2. Epub 2015 May 14.

Management of advanced basal cell carcinoma with hedgehog inhibitors: a real-world prospective comparative study.使用刺猬因子抑制剂治疗晚期基底细胞癌：一项真实世界前瞻性比较研究。

Clin Exp Dermatol. 2025 Aug 20. doi: 10.1093/ced/llaf383.

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.BOLT 研究：隆地替尼治疗基底细胞癌的 12 个月分析：一项评价晚期基底细胞癌患者接受 sonidegib 治疗的 II 期、随机、双盲研究。

J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5. doi: 10.1016/j.jaad.2016.02.1226. Epub 2016 Apr 7.

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: a Retrospective Study.索尼替尼治疗局部晚期基底细胞癌：一项回顾性研究。

Acta Derm Venereol. 2022 May 23;102:adv00740. doi: 10.2340/actadv.v102.1995.

Locally advanced basal cell carcinoma: Real-life data with sonidegib.局部晚期基底细胞癌：索立德吉的真实世界数据。

Dermatol Ther. 2022 Jun;35(6):e15441. doi: 10.1111/dth.15441. Epub 2022 Mar 21.

Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data.索纳替尼治疗局部晚期基底细胞癌：一项单中心回顾性研究及已发表的真实世界数据综述

Cancers (Basel). 2023 Jul 14;15(14):3621. doi: 10.3390/cancers15143621.

Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.索立德吉治疗晚期基底细胞癌的长期疗效和安全性：II 期随机、双盲 BOLT 研究的 42 个月分析。

Br J Dermatol. 2020 Jun;182(6):1369-1378. doi: 10.1111/bjd.18552. Epub 2019 Dec 8.

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma.索尼替尼治疗局部晚期基底细胞癌。

Actas Dermosifiliogr (Engl Ed). 2021 Apr;112(4):295-301. doi: 10.1016/j.ad.2020.11.002. Epub 2020 Nov 13.

Experience with sonidegib in patients with advanced basal cell carcinoma: case reports.晚期基底细胞癌患者使用索尼德吉的经验：病例报告

Drugs Context. 2022 May 23;11. doi: 10.7573/dic.2022-3-8. eCollection 2022.

本文引用的文献

Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.西米普利单抗用于刺猬抑制剂治疗后局部晚期基底细胞癌患者的2期开放标签、多中心、单臂研究：延长随访

J Am Acad Dermatol. 2024 Feb;90(2):414-418. doi: 10.1016/j.jaad.2023.08.111. Epub 2023 Oct 14.

Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.晚期基底细胞癌意大利患者人群的临床特征及 Hedgehog 通路抑制剂安全性和有效性的真实世界评估。

Dermatology. 2023;239(6):868-876. doi: 10.1159/000531280. Epub 2023 Jun 13.

Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.在现实临床环境中，索尼德吉作为局部晚期基底细胞癌的治疗方法：一项全国多中心研究。

Actas Dermosifiliogr. 2023 Jul-Aug;114(7):565-571. doi: 10.1016/j.ad.2023.04.022. Epub 2023 Apr 23.

Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance.刺猬通路抑制剂作为靶向癌症治疗药物和克服耐药性的策略。

Int J Mol Sci. 2022 Feb 3;23(3):1733. doi: 10.3390/ijms23031733.

Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.局部晚期基底细胞癌中维莫德吉内在耐药的频率和基因组方面。

Clin Cancer Res. 2022 Apr 1;28(7):1422-1432. doi: 10.1158/1078-0432.CCR-21-3764.

Br J Dermatol. 2020 Jun;182(6):1369-1378. doi: 10.1111/bjd.18552. Epub 2019 Dec 8.

Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.小分子抑制剂在治疗皮肤基底细胞癌中的 Hedgehog 通路作用。

Am J Clin Dermatol. 2018 Apr;19(2):195-207. doi: 10.1007/s40257-017-0319-4.

Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.索立德吉治疗局部晚期和转移性基底细胞癌患者的长期疗效和安全性：随机 2 期 BOLT 研究的 30 个月分析。

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):372-381. doi: 10.1111/jdv.14542. Epub 2017 Nov 6.

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.Erivance 关键性基底细胞癌（BCC）研究：维莫德吉治疗晚期 BCC 的疗效和安全性 12 个月更新。

J Am Acad Dermatol. 2015 Jun;72(6):1021-6.e8. doi: 10.1016/j.jaad.2015.03.021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验